Lewis A. Conner memorial lecture: Mechanisms leading to myocardial infarction: Insights from studies of vascular biology

Circulation

Volumn 90, Issue 4 I, 1994, Pages 2126-2146

  Fuster, Valentin ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID;

CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; CORONARY BLOOD VESSEL; HEART INFARCTION; HUMAN; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

CORONARY ARTERIOSCLEROSIS; CORONARY THROMBOSIS; CORONARY VESSELS; HUMAN; LIPIDS; MYOCARDIAL INFARCTION;

EID: 0028519887     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.90.4.2126     Document Type: Article

References (278)

1. American Heart Association. Heart and Stroke Facts. Dallas, Tex: American Heart Association National Center; 1992.
2. Cooper ES. Prevention: the key to progress. Circulation. 1993;24: 629-632. AHA Medical/Scientific Statement.
3. WHO-MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization Monica Project: registration procedures, event rates, and care-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994; 90:583-612.
4. Muller JE, Abela GS, Nesto RW, Tofler GH. Triggers, acute risk factors and vulnerable plaques: the lexicon of a new frontier. J Am Coll Cardiol. 1994;23:809-813.
5. Obrastzow WP, Straschesko ND. Zur Kenntnis der Thrombose der Koronararterien des Herzens. Z Klin Med. 1910;71:116-132.
6. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA. 1912;59:2015-2020.
7. Fye WB. Acute myocardial infarction: a historical summary. In: Gersh BJ, Rahimtoola SH, eds. Current Topics in Cardiology. New York, NY: Elsevier; 1991:1-13.
8. Fletcher AP, Sherry S, Alkjaersig N. The maintenance of sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest. 1959;38:1111-1119.
9. Sones FM Jr, Shirey EK, Proudfit WL, Westcott RN. Cinecoronary arteriography. Circulation. 1959;20:773. Abstract.
10. Favaloro RG, Effler DB, Groves LK, Sheldon WC, Sones FM Jr. Direct myocardial revascularization by saphenous vein graft: present operative techniques and indications. Ann Thorac Surg. 1970; 10:97-110.
11. Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301:61-68.
12. Constantinides P. Plaque fissures in human coronary thrombosis. J Athero Res. 1966;6:1-7.
13. Chazov EI, MAtveeva LS, Masaev AV, et al. Intracoronary administration of fibrinolysis in acute myocardial infarct. Ter Arkh. 1976; 48:8-19.
14. Rentrop P, Blanke H, Karsch KR, Kaiser H, Kostering H, Leitz K. Selective intracoronary thrombolysis in acute myocardial infarction and unstable angina pectoris. Circulation. 1981;63:307-317.
15. Ganz W, Ninomiya K, Hashida J, Fishbein MC, Buchbinder N, Marcus H, Mondkar A, Maddahi J, Shah PK, Berman D, Charuzi Y, Geft I, Shell W, Swan HJ. Intracoronary thrombolysis in acute myocardial infarction: experimental background and clinical experience. Am Heart J. 1981;102:1145-1149.
16. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
17. Willerson JT, Campbell WB, Winniford MD, Schmitz J, Apprill P, Firth BG, Ashton J, Smitherman T, Bush L, Buja LM. Conversion from chronic to acute coronary artery disease: speculation regarding mechanism. Am J Cardiol. 1984;54:1349-1354.
18. Davies MJ, Thomas AC. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J. 1985;53:363-373.
19. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation. 1985; 71:699-708.
20. GISSI (Gruppo Italiano Per Lo Studio Della Streptochinasi Nell-Infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-402.
21. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
22. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med. 1992;326:242-250.
23. Chesebro JH, Webster MWI, Zoldhelyi P, Roche PC, Badimon L, Badimon JJ. Antithrombotic therapy and progression of coronary artery disease. Circulation. 1992;86(suppl III):III-100-III-111.
24. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Definitions of advanced types of atherosclerotic lesions and a historical classification of atherosclerosis. Circulation. In press.
25. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis. 1989;99(suppl I):I-19-I-32.
26. Stary HC. Composition and classification of human atherosclerotic lesions. Virch Arch Pathol Anat. 1992;421:277-290.
27. Glagov S, Zarins C, Giddens DP, Ku DN. Hemodynamics and atherosclerosis: insights and perspectives gained from studies of human arteries. Arch Pathol Lab Med. 1988;112:1018-1831.
28. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-808.
29. Steinberg D. Antioxidants and atherosclerosis: a current perspective. Circulation. 1991;86:1420-1425.
30. Rosenfeld ME, Pestel E. Cellularity of atherosclerotic lesions. Cor Art Dis. 1994;5:189-197.
31. Watanabe Y, Inaba T, Simano H, Gotoda T, Yumamoto K, Mokuno H, Sato H, Yazaki Y, Yamada N. Induction of LDL receptor-related protein during differentiation of monocytemacrophages: possible involvement in the atherosclerotic process. Arterio Thromb. 1994;14:1000-1006.
32. Steinberg D, and Workshop Participants. Antioxidants in the prevention of human atherosclerosis. Circulation. 1992;85:2338.
33. Navab M, Hama SY, Nguyen TB, Fogelman AM. Monocyte adhesion and transmigration in atherosclerosis. Cor Art Dis. 1994; 5:198-204.
34. Kim JA, Territo MC, Wayner E, Carlos TM, Parhami F, Smith CW, Haberland ME, Fogelman AM, Berliner JA. Partial characterization of leukocyte binding molecules on endothelial cells induced by minimally oxidized LDL. Arterio Thromb. 1994;24: 427-433.
35. Faruqi RM, DiCorieto PE. Mechanisms of monocyte recruitment and accumulation. Br Heart J. 1993;69(suppl):S9-S29.
36. Stary HC, Chandler AB, Glagov S, Guyton JR. Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-2478.
37. Reichl D, Miller NE. Pathophysiology of reverse cholesterol transport: insights from inherited disorders of lipoprotein metabolism. Arteriosclerosis. 1989;9:785-797.
38. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Pathogenesis of coronary artery disease and the acute coronary syndromes (part II). N Engl J Med. 1992;326:310-318.
39. Heinecke JW. Cellular mechanisms for the oxidative modification of lipoproteins: implications for atberogenesis. Cor Art Dis. 1994; 5:205-210.
40. Willerson JT, Yao S-K, McNatt J, Benedict CR, Anderson HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic flow alterations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A. 1991;88:10624-10628.
41. Ambrose J, Tannenbaum M, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol. 1988;12: 56-62.
42. Davies MJ, Bland MJ, Hangartner WR, Angelini A, et al. Factors influencing the presence or absence of acute coronary thrombi in sudden ischemic death. Eur Heart J. 1989;10:203-208.
43. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis: characteristics of coronary atherosclerotic plaques underlying fatal occlusion thrombi. Br Heart J. 1983;50:127-134.
44. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographie morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985;5:609-616.
45. Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, Kass R, Blanche C, Matloff J, Morgenstern L. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med. 1986;315:913-919.
46. Ambrose JA, Hjemdahl-Monsen CE, Borrico S, Gorlin R, Fuster V. Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. Am J Cardiol. 1988;61:244-247.
47. Levin DC, Fallon JT. Significance of the angiographic morphology of localized coronary stenosis: histopathologic correlations. Circulation. 1982;66:316-320.
48. Moise A, Lesperance J, Theroux P, Taeymans Y, Goulet C, Bourassa MG. Clinical and angiographic predictors of new total coronary occlusion in coronary artery disease: analysis of 313 nonoperated patients. Am J Cardiol. 1984;54:1176-1181.
49. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol. 1986;7:472-478.
50. Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, Santamore WP. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
51. Nobuyoshi M, Tanaka M, Mosaka H, Kimura T, Yokoi H, Hamasaki N, Kim K, Shindo T, Kimura K. Progression of coronary atherosclerosis: is coronary spasm related to progression? J Am Coll Cardiol. 1991;18:904-910.
52. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992;69: 729-732.
53. Brown BG, Gallery CA, Badger RS, Kennedy JW, Mathey D, Bolson EL, Dodge HT. Incomplete lysis of thrombus in the moderate underlying atherosclerotic lesion during intracoronary infusion of streptokinase for acute myocardial infarction: quantitative angiographic observations. Circulation. 1986;73:653-661.
54. Nissen SE, Gurley JC, Grines CL, Booth DC, McClure R, Berk M, Fischer C, DeMaria AN. Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease. Circulation. 1991;84:1087-1099.
55. Ge J, Erbel R, Gerber T, Gunter G, et al. Intravascular ultrasound imaging of angiographically normal coronary arteries: a prospective study in vivo. Br Heart J. 1994;71:572-578.
56. Hangartner JRW, Charleston AJ, Davies MJ, Thomas AC. Morphological characteristics of clinically significant coronary artery stenosis in stable angina. Br Heart J. 1986;56:501-508.
57. Richardson RD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;2:941-944.
58. Toussaint J-F, Southern JF, Falk E, Fuster V, Kantor HL. Atherosclerotic plaque components imaged by nuclear magnetic resonance. Arterioscler Thromb. In press.
59. 13C-NMR spectroscopy of human atherosclerotic lesions: relation between fatty acid saturation, cholesteryl ester content and luminal obstruction. Arterio Thromb. In press.
60. Van de Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
61. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophages, and smooth muscle cell content. Br Heart J. 1993;69:377-381.
62. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation. 1994;90:775-778.
63. 2 inhibitor: importance of activated monocytes. Cor Art Dis. 1994;5:137-145.
64. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Location of stromelysin gene in atherosclerotic plaques using in situ hybridization. Proc Natl Acad Sci USA. 1991;88:8154-8158.
65. Shah PK, Falk E, Badimon JJ, Levy G, Fernandez Ortiz A, Fallon J, Fuster V. Human monocyte-derived macrophages express collagenase and induce collagen breakdown in atherosclerotic fibrous caps: implication for plaque rupture. Circulation. 1993; 88(suppl I):I-254. Abstract.
66. Buja LM, Willerson JT. Role of inflammation in coronary plaque disruption. Circulation. 1994;89:503-505.
67. Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 1992;71:850-858.
68. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and atable atherosclerotic lesions: a structural analysis with histopathological correlation. Circulation. 1993;87:1179-1187.
69. MacIsaac AL, Thomas JD, Topol EJ. Toward the quiescent coronary plaque. J Am Coll Cardiol. 1993;22:1228-1241.
70. Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993;88:1444-1455.
71. 1988 Joint National Committee. The 1988 report of the Joint National Committee on detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1988;148:1023-1038.
72. Fischer GM, Swain ML, Cherian K. Increased vascular collagen and elastin synthesis among major vessels. Atherosclerosis. 1980; 35:11-20.
73. Leung DYM, Glagov S, Mathews MB. Cyclic stretching stimulates synthesis of matrix components by arterial smooth muscle cells in vitro. Science. 1976;191:475-477.
74. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation: positive correlation between plaque location and low and oscillating shear stress. Arteriosclerosis. 1985;5:293-302.
75. Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Structure-dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques. Circulation. 1991;83: 1764-1770.
76. Taeymans Y, Theroux P, Lesperance J, Waters D. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation. 1992;85:78-85.
77. Gibson CM, Diaz L, Kandarpa K, Sacks FM, Pasternak RC, Sandor T, Feldman C, Stone PH. Relation of the vessel wall shear stress to atherosclerosis progression in human coronary arteries. Arterio Thromb. 1993;12:310-315.
78. Gotsman M, Rosenheck S, Nassar H, Weiber S, Sapoznikov D, Mosseri M, Weiss A, Lotan C, Rozenman Y. Angiographic findings in the coronary arteries after thrombolysis in acute myocardial infarction. Am J Cardiol. 1992;70:715-723.
79. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT. Mechanical properties of model atherosclerotic lesion lipid pools. Athero Thromb. 1994;14:230-234.
80. Barger AC, Beeuwkes R III. Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol. 1990; 66:41G-43G.
81. Gibson CM, Diaz L, Kandarpa K, et al. Relation of vessel wall shear stress to atherosclerosis progression in human coronary arteries. Athero Thromb. 1993;13:310-315.
82. Wilcox JN. Thrombotic mechanisms in atherosclerosis. Cor Art Dis. 1994;5:223-229.
83. Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type 1: a model of deep vessel injury: influence of blood rheology, von Willebrand factor, and blood coagulation. Circulation. 1988;78:1432-1442.
84. Badimon L, Badimon JJ. Mechanism of arterial thrombosis in nonparallel streamlines: platelet thrombi grow at the apex of stenotic severely injured vessel wall: experimental study in the pig model. J Clin Invest. 1989;84:1134-1144.
85. Capone G, Wolf NM, Meyer B, Meister SG. Frequency of intracoronary filling defects by angiography in unstable angina pectoris at rest. Am J Cardiol. 1985;56:403-406.
86. Pozzati A, Bugiardini R, Borghi A, Ottani A, Muzi A, Morgagni G, Puddu P. Transient ischemia refractory to conventional medical treatment in unstable angina: angiographic correlates and prognostic implications. Eur Heart J. 1992;13:360-365.
87. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
88. Richardson SG, Allen DC, Morton P, Murtagh JG. Pathological changes after intravenous streptokinase treatment in eight patients with acute myocardial infarction. Br Heart J. 1989;61: 390-395.
89. Davis MJ. Successful and unsuccessful coronary thrombolysis. Br Heart J. 1989;61:381-384.
90. Davies SW, Marchant B, Lyons JP, Timmis AD. Irregular coronary lesion morphology after thrombolysis predicts early clinical instability. J Am Coll Cardiol. 1991;18:669-674.
91. de Cesare NB, Ellis SG, Williamson PR, Deboe SF, Pitt B, Mancini GB. Early reocclusion after successful thrombolysis is related to lesion length and roughness. Cor Art Dis. 1993;4: 159-166.
92. Mailhac A, Badimon JJ, Fallon JT, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L. Effect on an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: relative contribution on fibrin(ogen) and platelet. Circulation. In press.
93. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol. 1994;23:1564-1569.
94. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissue: implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134: 1087-1097.
95. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro J. Insights into the pathogenesis of acute ischemic syndromes. Circulation. 1988;77:1213-1220.
96. Rentrop KP, Felt F, Blanke H, Sherman W, Thornton JC. Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Circulation. 1989;80: 1166-1175.
97. Van Lierde J, DeGeest H, Verstraete M, Van de Werf F. Angiographic assessment of the infarct-related residual coronary stenosis after spontaneous or therapeutic thrombolysis. J Am Coll Cardiol. 1990;16:1545-1549.
98. Hackett D, Davie G, Ghierchia S, Maseri A. Intermittent coronary occlusion in acute myocardial infarction: value of combined thrombolytic and vasodilatory therapy. N Engl J Med. 1987;317:1055-1059.
99. Ohman EM, Topol EJ, Califf RM, Bates ER, Ellis SG, Kereiakes DJ, George BS, Samaha JK, Kline E, Sigmon KN. An analysis of the cause of early mortality after administration of thrombolytic therapy. Cor Art Dis. 1993;4:957-964.
100. Lassila R, Badimon JJ, Vallabhajosula S, Badimon L. Dynamic monitoring of platelet deposition on severely damaged vessel wall in flowing blood: effects of different stenosis on thrombus growth. Arteriosclerosis. 1990;10:306-315.
101. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesbro JH, Fuster V, Badimon L. Therapeutic probes to inhibit thrombus growth on fresh mural thrombus: role of thrombin inhibition. Circulation. In press.
102. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparinantithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
103. Francis CW, Markham RE Jr, Barlow GH, Florack TM, Dorbrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med. 1983;102:220-230.
104. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.Proc Natl Acad Sci USA. 1989; 86:7585-7589.
105. Owen J, Friedman KD, Grossman BA, Wilkins C, Berke AD, Powers ER. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood. 1988;72:616-620.
106. Eisenberg PR, Sherman LA, Jaffe AS. Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol. 1987; 10:527-529.
107. Maseri A, L'Abbate A, Baroldi G, et al. Coronary vasospasm as a possible cause of myocardial infarction: a conclusion derived from the study of 'preinfarction' angina. N Engl J Med. 1978;299: 1271-1277.
108. Bertrand M, Lablanch LM, Tilmant P, et al. Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography. Circulation. 1982;65:1299-1306.
109. Vane JR, Anggaard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
110. Moncada S, Gryglewski R, Bunting S, Vane SR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature. 1976;263:663-665.
111. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;299:372-376.
112. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
113. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411-415.
114. McClellan G, Weisberg A, Rose D, Winegrad S. Endothelial cell storage and release of endothelin as a cardioregulatory mechanism. Circ Res. 1994;75:85-96.
115. Lerman A, Webster WMI, Chesebro JH, Edwards WD, Wei C-M, Fuster V, Burnett JC. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. Circulation. 1993;88: 2923-2928.
116. Zeiher AM, Drexler H, Wollschiager H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with difference early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
117. Chester AH, O'Neill GS, Moncada S, Tadjkarimi S, Yacoub MN. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet. 1990;336:897-900.
118. Lam JYT, Chesebro JH, Steele PM, Badimon L, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. Circulation. 1987; 75:243-248.
119. Vanhoutte PM, Shimokawa H. Endothelium-derived relaxing factor and coronary vasospasm. Circulation. 1989;80:1-9.
120. Bogaty P, Hackett D, Davies G, Maseri A. Vasoreactivity of the culprit lesion in unstable angina. Circulation. 1994;90:5-11.
121. Schecter AD, Chesebro JH, Fuster V. Refractory Prinzmetal's angina treated with cyproheptadine. Ann Intern Med. 1994;121: 113-114.
122. Fischell TA, Derby G, Tse TML, Stadius ML. Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. Circulation. 1988;78:1323-1334.
123. El-Tamini H, Davies GJ, Hackett D, Sritara P, Bertrand O, Crea F, Maseri A. Abnormal vasomotor changes early after coronary angioplasty. Circulation. 1991;84:1198-1202.
124. Araki H, Nishi K, Jougasaki M. Effects of thrombosis on vascular tone in rate mesenteric arteries with endothelium in vivo. Circ Res. 1990;67:312-318.
125. Badimon L, Lassila R, Badimon J, Fuster V. An acute surge of epinephrine stimulates platelet deposition to severely damaged vascular wall. J Am Coll Cardiol. 1990;15(suppl):181A. Abstract.
126. Hjemdahl P, Larsson PT, Waller NH. Effects of stress and β-blockade on platelet function. Circulation. 1991;84(suppl III): III-44-III-61.
127. Larsson PT, Wallen NH, Hjemdahl P. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation. 1994;89:1951-1957.
128. Kimura S, Nishinaga M, Ozawa T, Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J. 1994;128:7-11.
129. Grignani G, Soffiantino F, Zucchella M, Pacchiarini L, Tacconi F, Bonomi E, Pastoris A, Sbaffi A, Fratino P, Tavazzi L. Platelet activation by emotional stress in patients with coronary artery disease. Circulation. 1991;83(suppl II):II-128-II-136.
130. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1991;325: 1551-1556.
131. Dimsdale JE, Ziegler MG. What do plasma and urinary increases of catecholamines tell us about human response to stressors? Circulation. 1991;83(suppl III):III-36-III-42.
132. Tofler GH, Brezinski D, Schafer AL, Czeisler CA, Rutherford JD, Willich SN, Gleason RE, Williams GH, Muller JE. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316:1514-1518.
133. Goldberg RJ, Brady P, Muller JE, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol. 1990;66: 140-144.
134. Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Godlberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy physical exertion. N Engl J Med. 1993;329:1677-1683.
135. Lin CS, Penha PD, Zak FG, Lin CJ. Morphodynamic interpretation of acute coronary thrombosis, with special reference to volcano-like eruption of atheromatous plaque caused by coronary artery spasm. Angiology. 1988;39:535-547.
136. Yamagishi M, Miyatake K, Tamai J, Nakatani S, Koyama J, Nissen SE. Intravascular ultrasound detection of atherosclerosis at the site of focal vasospasm in angiographically normal or minimally narrowed coronary segments. J Am Coll Cardiol. 1994;23: 352-357.
137. Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young adult: effects of cigarette smoking, strong family history, and medical therapy. Circulation. 1981;63:546-551.
138. Winniford MD, Wheeland KR, Kremers MS, Ugolini V, van den Berg E Jr, Niggemann EH, Jansen DE, Hillis LD. Smoking-induced coronary vasoconstriction in patients with atherosclerotic coronary artery disease: evidence for adrenergically mediated alterations in coronary artery tone. Circulation. 1986;73:662-667.
139. Cullen JW, McKenna JW, Massey MM. International control of smoking and the US experience. Chest. 1986;89(suppl):206S-218S.
140. Buhler FR, Vesanen K, Watters JT, Bolli P. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. Am Heart J. 1988;115:282-288.
141. Paul O. Background of the prevention of cardiovascular disease. II. Arteriosclerosis, hypertension, and selected risk factors. Circulation. 1989;80:206-214.
142. Gawin FH. Cocaine addition: psychology and neurophysiology. Science. 1991;251:1580-1586.
143. Killam AI. Cardiovascular and thrombosis pathology associated with cocaine use. Hemat/Oncol Clin North Am. 1993;7:1143.
144. Moliterno DJ, Willard JF, Lange RA, Negus BH, Boehrer JD, Glamann DB, Landau C, Rossen JD, Winniford MD, Hillis LD. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med. 1994;330:454-459.
145. Welder AA, Meichert RB. Cardiotoxic effects of cocaine and anabolic-androgenic steroids in the athlete. J Pharm Toxicol. 1993;29:61-68.
146. Lange RA, Cigarroa RG, Yancy CW Jr, Willard JE, Popma JJ, Sills MN, McBride W, Kim AS, Hillis LD. Cocaine-induced coronary artery vasoconstriction. N Engl J Med. 1989;321: 1557-1562.
147. Lange RA, Cigarroa RG, Flores ED, McBride W, Kim AS, Wells PJ, Bedotto JB, Danziger RS, Hillis LD. Potentiation of cocaine-induced coronary vasoconstriction by beta-adrenergic blockade. Ann Intern Med. 1990;112:897-903.
148. Minor RL, Scott BD, Brown DD. Cocaine-induced myocardial infarction in patients with normal coronary arteries. Ann Intern Med. 1991;115:797-806.
149. Om A, Ellahham S, Ornato JP, Picone C, Theogaraj J, Corretjer GP, Vetrovec GW. Medical complications of cocaine: possible relationship to low plasma cholinesterase enzyme. Am Heart J. 1993;125:1114-1128.
150. Alderman MH, Madhaven S, Ooi WL. Association of the reninsodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
151. Meade TW, Cooper JA, Peart WS. Plasma renin activity and ischemic heart disease. N Engl J Med. 1993;329:616-619.
152. Cambien F, Poirier O, Lecerp L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641-644.
153. Swales JD. ACE gene: the plot thickens. Lancet. 1993;342: 1065-1066.
154. Kaski JC, Rosano G, Gavrielides S, Chen L. Effects of angiotensin-converting enzyme inhibition on exercise-induced angina and ST segment depression in patients with microvascular angina. J Am Coll Cardiol. 1994;23:652-657.
155. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Baughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 1993;87:1969-1973.
156. van Leeuwen RTJ, Kol A, Andreotti F, Kluft C, Masseri A, Sperti G. Angiotensin II increases plasminogen activator inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 1994;90: 362-368.
157. Malik KU, Nasjsletti MD. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res. 1976;38:26-30.
158. Wright RA, Flapan AD, Alberti KGMM, Ludiam CA. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol. 1994;24: 67-73.
159. Rader DJ, Hoeg JM, Brewer HB Jr. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med. 1994;120:1012-1025.
160. Hunt BJ. The relation between abnormal hemostatic function and the progression of coronary disease. Curr Opin Cardiol. 1990;5: 758-765.
161. Badimon JJ, Badimon L, Turitto VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels: in vivo study in the rabbit model. Arterio Thromb. 1991;11: 395-402.
162. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987; 30:132-137.
163. Frank SL, Klisak I, Sparkes RS, Mohandas T, Tomlinson JE, McLean JW, Lawn RM, Lusis AJ. The apoprotein(a) gene resides on human chromosome 6q26-27 in close proximity to the homologous gene for plasminogen. Hum Genet. 1988;79:352-356.
164. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis. 1990;10:672-679.
165. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA. 1993; 270:2195-2199.
166. Kostner GM, Czinner A, Pfeiffer KH, Bihari-Varga M. Lipoprotein(a) concentrations as indicators for atherosclerosis. Arch Dis Child. 1991;66:1054-1056.
167. Racial (black/white) differences in serum lipoprotein(a) distribution and its relation to parental myocardial infarction in children: Bogalusa Heart Study. Circulation. 1991;84:160-167.
168. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of apo(a) gene, apo(a) glycoprotein and plasma concentrations of Lp(a) in three ethnic groups: evidence for no conversion 'null' at the apo(a) locus. JCI. 1994;93:2526-2534.
169. Boers GHJ, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JA, Schoonderwaldt HC, Kleijer WJ, Kloppenborg PW. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 1985;33:709-715.
170. Genest JJ Jr, McNamara JR, Upson B, Salem DN, Ordovas JM, Schaefer EJ, Malinow MR. Prevalence of familial hyperhomocyst(e)inemia in men and premature coronary artery disease. Arterio Thromb. 1991;11:1129-1136.
171. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced atherosclerosis: the role of endothelial cell injury and platelet response in its genesis. J Clin Invest. 1976;58:731-741.
172. Getz GS. Report on the Workshop on Diabetes and Mechanisms of Atherogenesis (September 17th and 18th, 1992, Bethesda, Maryland). Arterio Thromb. 1993;13:459-464.
173. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
174. Schwartz CJ, Kelley JL, Valente AJ, Cayatte AJ, Sprague EA, Rozek MM. Pathogenesis of the atherosclerotic lesion: implications for diabetes mellitus. Diabetes Care. 1992;15:1156-1167.
175. Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetes mellitus. Ann Intern Med. 1975;82: 733-738.
176. Schneider DJ, Sobel BE. Effect of diabetes on the coagulation and fibrinolytic systems and its implications for atherogenesis. Cor Art Dis. 1992;3:26-32.
177. Colwell JA, Sagel J, Crook L. Correlation of platelet aggregation, plasma factor activity and megathrombocytes in diabetic subjects with and without vascular disease. Metabolism. 1977;26:279-285.
178. Bensoussan D, Levy-Toledano S, Passa P, Caen J, Caniver J. Platelet hyperaggregation and increased plasma level of von Willebrand factor in diabetics with retinopathy. Diabetologgia. 1975;11:307-312.
179. Jacoby RM, Nesto RW. Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. J Am Coll Cardiol. 1992;20:736-744.
180. Reichard P, Nilsson B-Y, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329: 304-309.
181. Olofsson BO, Dahlen G, Nilsson TK. Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J. 1989;10:77-82.
182. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, Blomback M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987;2:3-9.
183. Aznar J, Estelles A, Tormo G, Sapena P, Tormo V, Blanch S, Espana F. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease. Br Heart J. 1988;59:535-541.
184. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med. 1990;113:88-93.
185. Lam JYT, Latour JG, Lesperance J, Waters D. Platelet aggregation, coronary artery disease progression and future coronary events. Am J Cardiol. 1994;73:333-338.
186. Merlini PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90:61-68.
187. Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980; 1:1050-1054.
188. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
189. Kannel WB, D'Agostino RB, Belanger AJ. Fibrinogen, cigarette smoking, and risk of cardiovascular disease: insights from Framingham Study. Am Heart J. 1897;113:1006-1010.
190. Meade TW, Miller GJ, Rosenberg RD. Characteristics associated with the risk of arterial thrombosis and the prothrombotic state. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders; 1992:79-97.
191. McGill DA, Ardlie NG. The relationship between blood fibrinogen level and coronary artery disease. Cor Art Dis. 1990;1: 557-566.
192. Rosengren A, Wilhelmsen L, Wellin L, Tsipogianni A, Teger-Nilsson AC, Wedel H. Social influences and cardiovascular risk factor as determinants of plasma fibrinogen concentration in a general population sample of middle aged men. BMJ. 1990;330: 634-638.
193. Scarabin PY, Bonothon-Kopp C, Bara L, Malmeja A, Guize L, Samama M. Factor VII activation and menopausal status. Thromb Res. 1990;57:227-234.
194. Braunwald E. Unstable angina: a classification. Circulation. 1989; 80:410-414.
195. Flugelman MY, Virmani R, Correa R, Yu ZX, Farb A, Leon MB, Elaimi A, Fu YM, Casscells W, Epstein SE. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina: a clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation. 1993;88:2493-2500.
196. Gotoh H, Minamino T, Hatoh O, Hamano Y, Fukui S, Hori M, Kusuoka H, Mishima M, Inoue M, Kamada T. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Circulation. 1988;77:526-534.
197. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE, Swain JA, Topol EJ, Willerson JT. Diagnosis and managing unstable angina. Circulation. 1994;90: 613-622.
198. DeWood MA, Stifter WF, Simpson CS, Spores J, Eugster GS, Judge TP, Hinnen ML. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med. 1986;315: 417-423.
199. Fuster V, Frye RL, Kennedy MA, Connolly DC, Makin HT. The role of collateral circulation in the various coronary syndromes. Circulation. 1979;59:1137-1144.
200. Gibson RS, Beller GA, Gheorghiade M, Nygaard TW, Watson DD, Huey BL, Sayre SL, Kaiser DL. The prevalence and clinical significance of residual myocardial ischemia two weeks after uncomplicated non-Q-wave infarction: a prospective natural history study. Circulation. 1986;73:1186-1198.
201. Timmis AD, Griffin B, Crick JCP, Nelson DJ, Sowton E. The effects of early coronary patency on the evolution of myocardial infarction: a prospective angiographic study. Br Heart J. 1987;58: 345-351.
202. Davies MJ, Woolf N, Rowles PM, Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J. 1988;60:459-464.
203. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro J. Atherosclerosis plaque rupture and thrombosis: evolving concepts. Circulation. 1990;86(suppl III):III-47-III-59.
204. Maseri A, Crea KF, Cianflone D. Myocardial ischemia caused by distal coronary vasoconstriction. Am J Cardiol. 1992;70:1602-1605.
205. Reddy KG, Nair RN, Sheehan HM, Hodgson JM. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 1994;23:833-843.
206. Egashita K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilitation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;23:1659-1664.
207. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R. Influence of coronary collateral vessels on myocardial infarct size in humans: results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Circulation. 1991;83:739-746.
208. Cohen M, Sherman W, Rentrop KP, Gorlin R. Determinants of collateral filling observed during sudden controlled coronary artery occlusion in human subjects. J Am Coll Cardiol. 1989;13: 297-303.
209. Patterson RE, Jones-Collins BA, Aamodt R, Ro YM. Differences in collateral myocardial blood flow following gradual vs abrupt coronary occlusion. Cardiovasc Res. 1993;17:207-213.
210. Cohen MV, Yipintsoi T, Scheuer J. Coronary collateral stimulation by exercise in dogs with stenotic coronary arteries. J Appl Physiol. 1982;52:664-671.
211. Bloor CM, White FC, Sanders M. Effect of exercise on collateral development in myocardial ischemia in pigs. J Appl Physiol. 1984; 56:656-665.
212. Liebson PR, Klein LW. Intravascular ultrasound in coronary atherosclerosis: a new approach to clinical assessment. Am Heart J. 1992;123:1643-1650.
213. Bartorelli AL, Neville RF, Leren G, et al. In vitro and in vivo intravascular ultrasound imaging. Eur Heart J. 1992;13:79-94.
214. St Gear FG, Pinto FJ, Alderman EL, Fitzgerald PJ, Stadius ML, Popp RL. Intravascular ultrasound imaging of angiographically normal coronary arteries: an in vivo comparison with quantitative angiography. J Am Coll Cardiol. 1991;18:952-958.
215. Nissen SE, Gurley JC, Booth DC, et al. Differences in intravascular ultrasound plaque morphology in stable and unstable patients. Circulation. 1991;84(suppl II):II-436. Abstract.
216. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest. 1989;60:455-461.
217. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85:1234-1241.
218. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic efforts of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidant in vivo can selectively inhibit low-density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA. 1987;84:7725-7729.
219. Blankenhorn DH, Hodis HN. Arterial imaging and atherosclerosis reversal. Arterio Thromb. 1994;14:177-192.
220. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease (based on FATS and other studies). Circulation. 1993;87:1781-1791.
221. Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ. Effects of therapy with cholestyramine on progression of coronary atherosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69:313-324.
222. Blankenhorn DH, Selzer RH, Mack WJ, Crawford DW, Pogoda J, Lee PL, Shircore AM, Azen SP. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures: a comparison of different measures of treatment effects (based on CLAS). Circulation. 1992;86:1701-1709.
223. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL. Can lifestyle changes reverse coronary artery disease? The Lifestyle Heart Trial. Lancet. 1990;336:129-133.
224. Buchwald H, Matts JP, Fitch LL, Campos CT, Sanmarco ME, Amplatz K, Castaneda-Zuniga WR, Hunter DW, Pearce MB, Bissett JK, for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events: Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA. 1992;268:1429-1433.
225. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ. Regresion of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens (USCF-SCOR). JAMA. 1990;264:2007-3012.
226. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, Mann JI, Swan AV. Effects on coronary artery disease of lipidlowering diet, or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-569.
227. Haskell WL, Alderman EL, Fair JM, Maron DJ, Mackey SF, Superko HR, Williams PT, Johnstone IM, Champagne MA, Krauss RM. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
228. Waters D, Higginson L, Gladstone P, Kimball B, Le May M, Boccuzzi SJ, Lesperance J. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis and Infarction Trial (CCAIR). Circulation. 1994;89:959-968.
229. Pearson TA, Marx HJ. The rapid reduction in cardiac events with lipid-lowering therapy: mechanisms and implications. Am J Cardiol. 1993;72:1073.
230. Gould KL, Martucci JP, Goldberg DI, Hess MJ, Edens RP, Latifi R, Duidrick SJ. Short-term cholesterol lowering decreased size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing coronary endothelium. Circulation. 1994;89:1530-1538.
231. Yusuf S, Peto J, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335-371.
232. Frishman WH, Lazer EJ. Reduction of mortality, sudden death and non-fatal reinfarction with beta-adrenergic blockers in survivors of acute myocardial infarction: a new hypothesis regarding the cardioprotective action of beta-adrenergic blockade. Am J Cardiol. 1990;66:66G-70G.
233. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med. 1992;327:669-677.
234. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
235. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992; 327:685-691.
236. Francis GS. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure. Am Heart J. 1989;118:642-648.
237. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation. 1994;89:493-498.
238. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
239. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-b expression in rat glomerular messangial cells. J Clin Invest. 1994;93:2431-2437.
240. Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation. 1994;90:449-455.
241. Foster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87: 659-675.
242. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation. 1994;89:1449-1468.
243. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: oral anticoagulants. Circulation. 1994;89:1469-1480.
244. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81-106.
245. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J. 1994;308:159-168.
246. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
247. Smith P. Antithrombotic therapy in the chronic phase myocardial infarction. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders; 1992:343-362.
248. MacMahon S, Collins R, Knight C, Yusuf S, Peto R. Reduction of major morbidity and mortality by heparin in acute myocardial infarction. Circulation. 1988;78(suppl II):II-98. Abstract.
249. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol. 1990;66:1412-1417.
250. Smith P, Arensen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990; 323:147-152.
251. Juul-Möller S, Edvardsson N, Jahnmatz B, Rosén A, Sørensen S, Ömblus R, SAPAT Group. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;340:1421-1425.
252. Chesbro JH, Webster MWI, Smith HC, Frye RL, Holmes DR, Reeder GS. Antiplatelet therapy in coronary disease progression: reduced infarction and new lesion formation. Circulation. 1989; 80(suppl II):II-266. Abstract.
253. Ridker PM, Manson JE, Gaziano JM, Buring JE, Hennekens CH. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial Ann Intern Med. 1991;114:835-839.
254. Report of the Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1980;2: 989-993.
255. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wierczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Alli J, Kronmal R, Fuster V. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: primary end points analysis from the ATACS trial. Circulation. 1994;89:81-88.
256. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleinman NS, Kerelakes DJ, Cohen M, Chapekis KA, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: a multicenter, randomized angiographic trial. Circulation. 1994;89:1557-1566.
257. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haughland JM, Anderson JL. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. J Am Coll Cardiol. 1994;23: 993-1003.
258. Fuchs J, McCabe CH, Antman EM, Borzak S, Palisaitis D, Herson S, Daum R, Palmeri S, Sequeira R, Sharma GVRK, Diver D, Warnica W, Mueller H, Magorien R, Goldberg N, Leya F, Thompson C, Williams D, Remertz M, Chakko S, Henry T, Hochman J, Chaitman B, Cannon C, Findlen K, Adelman B, Braunwald E, for the TIMI 7 Investigators. Hirulog in the treatment of unstable angina: results of the TIMI 7 trial. J Am Coll Cardiol. 1994;II:56A. Abstract.
259. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
260. Lidón RM, Théroux P, Lespérance J, Adelman B, Bonan R, Duval D, Lévesque J. A pilot, early angiographic patency study using a direct thrombus inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation. 1994;89:1567-1572.
261. Simoons ML, Jan de Boer M, Brand van den JBMM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken RL, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, De Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
262. Schulman SP, Goldschmidt-Clermont PJ, Navetta FI, Chandra NC, Guerci AD, Califf RM, Ferguson JJ, Willerson JT, Wolfe CL, Bahr R, Yakubov SJ, Nygaard TW, Mason SJ, Brashears L, Charo I, Du Mee C, Kitt MM, Gerstenblith G, Johns Hopkins Hospital, Baltimore Md. Integrelin in unstable angina: a double-blind randomized trial. Circulation. 1993;88(suppl II).
263. Kleiman NS, Ohman M, Califf RM, George BS, Kereiakes D, Aguirre FV, Weisman H, Schaible T, Topol EJ. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 1993;22:381-389.
264. Van de Bos AA, Deckers JW, Heyndrickx GR, Laarman GJ, Rijnierse J, Serruys PW, Suryapranata H, Zijlstra F. PTCA with Hirudin associated with less acute cardiac complications than with heparin. Circulation. 1992;86(suppl I):I-372. Abstract.
265. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, De Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of direct antithrombin Hirulog in place of heparin during coronary angioplasty. Circulation. 1993;87:1622-1629.
266. Tcheng JE, Ellis SG, Kleiman NS, Harrington RA, Mick MJ, Navetta FI, Worley S, Smith JE, Kereiakes DJ, Kitt MM, Miller JA, Sigmon KN, Califf RM, Topol EJ. Outcome of patients treated with the GPIIb/IIIa inhibitor integrelin during coronary angioplasty: results of the IMPACT study. Circulation. 1993; 88(suppl I):I-595. Abstract.
267. Stamper MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
268. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110.
269. Nabulsi AA, Folsom AR, White A, Patsch W, Heiss G, Wu KK, Szklo M. Association of hormone replacement therapy in various cardiovascular risk factors in postmenopausal women. N Engl J Med. 1993;328:1070-1075.
270. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
271. Rosano GMC, Sarrel PM, Poole-Wilson PA, Collins P. Beneficial effect of oestrogen on exercise-induced myocardial ischemia in women with coronary artery disease. Lancet. 1993; 342:133-136.
272. Magness RR, Rosenfeld CR. Local and systemic estradiol-17β: effects on uterine and systemic vasodilation. Am J Physiol. 1989; 256:E536-E542.
273. Ganger KF, Vyas S, Whitehead M, Crook D, Meire H, Campbell S. Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause. Lancet. 1991;338: 839-842.
274. Ginsberg J, Hardiman P, O'Reilly B. Peripheral blood flow in menopausal women who have hot flushes and in those who do not. BMJ. 1989;298:1488-1490.
275. Brass LM, Kisiel D, Sarrel PM. A correlation between estrogen and middle cerebral artery blood velocity at different times in the menstrual cycle in women with catamential migraines. J Cardiovasc Technol. 1990;9:68.
276. Collins P, Rosano GMC, Jiang C, Lindsay D. Cardiovascular protection by oestrogen - a calcium antagonist effect? Lancet. 1993;341:1264-1265.
277. Williams JK, Adams MR, Herrington DM, Clarkson TB. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J Am Coll Cardiol. 1992;20:452-457.
278. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease. Cardiovasc Clin. 1989;19:159-172.